Engineered immune cells take on glioblastoma in first human trial
NCT ID NCT07193628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new type of immunotherapy called CAR-T cells in 14 people with glioblastoma that has come back or not responded to treatment. The CAR-T cells are designed to target two proteins found on glioblastoma cells and are given directly into the fluid around the brain. The main goal is to see if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EPC-003 CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for patients with recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is a very early, small phase 1 trial with only 14 participants. It primarily tests safety, not effectiveness. There is a risk of serious side effects from the CAR-T cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••